Text Size

Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults

This study has been completed.
Sponsor:
Information provided by:
MedImmune LLC
ClinicalTrials.gov Identifier:
NCT00192127
First received: September 12, 2005
Last updated: December 12, 2007
Last verified: December 2007
History of Changes
  Purpose

This study is to assess the safety of a bivalent vaccine of two new 6:2 influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine (FluMist) containing them.


Condition Intervention Phase
Influenza
 Biological: FluMist
Other: Placebo
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Official Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults

Resource links provided by NLM:

MedlinePlus related topics: Flu
U.S. FDA Resources

Further study details as provided by MedImmune LLC:

Primary Outcome Measures:
  • The primary endpoint of this study is fever (Day 0-7) defined as oral temperature ³101°F. [ Time Frame: Day 0-7 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Secondary endpoints of the study include other reported reactogenicity events and other adverse events that occur within seven days (Day 0-7) and fourteen days (Day 0-14) following vaccination [ Time Frame: Days 0-7; 0-14 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 300
Study Start Date: August 2004
Study Completion Date: February 2005
Arms Assigned Interventions
Active Comparator: 1
FluMist
 Biological: FluMist
A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0.
Placebo Comparator: 2
Placebo
 Other: Placebo
A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0

Detailed Description:

The primary study objective is to assess the safety of a bivalent vaccine of two new 6:2 influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine (FluMist) containing them. Safety will be demonstrated by similar fever rates (oral temperature ≥101°F Days 0-7) in vaccine and placebo recipients.

  Eligibility

Ages Eligible for Study:   18 Years to 49 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 18-49 years of age (not yet reached their 50th birthday);
  • In good health;
  • Available by telephone;
  • Ability to understand and comply with the requirements of the protocol; and
  • Signed informed consent and HIPAA authorization.

Exclusion Criteria:

  • Any condition for which the inactivated influenza vaccine is indicated, including: chronic disorders of the pulmonary or cardiovascular systems, including asthma; chronic metabolic diseases (including diabetes mellitus) renal dysfunction, or hemoglobinopathies which required regular medical follow-up or hospitalization during the preceding year;
  • Acute febrile (>100.0°F oral) and/or respiratory illness, including cough or sore throat, within the 14 days prior to enrollment;
  • Hypersensitivity to egg or egg protein;
  • Hypersensitivity to gentamicin;
  • Any known immunosuppressive condition or immune deficiency disease, including HIV infection, or ongoing immunosuppressive therapy;
  • History of Guillan-Barré Syndrome;
  • Household contact who is immunocompromised (participant should also avoid close contact with immunocompromised individuals for at least 21 days);
  • Participation in another investigational trial within 30 days prior to enrollment or expected enrollment in another investigational trial during this study;
  • Chronic or regular use of antipyretic or analgesic medication on a daily or every other day basis; Notes: A daily dose of 81 mg of aspirin is not considered a contraindication to enrollment. Discontinuation of prophylactic use of antipyretic or analgesic medications at the time of enrollment and for fourteen days following vaccination is not considered a contraindication to enrollment.
  • Pregnancy or, in biologically capable women (e.g., menses within the last year) participant does not agree to use acceptable birth control measures as determined by the investigator continuously for three months after enrolling into the study (for those biologically capable, a urine pregnancy test must be performed on the day of vaccination with a negative result);
  • Breastfeeding or lactating women;
  • Administration of intranasal medications within two weeks prior to enrollment or expected receipt during this study;
  • Employees of the investigational site or their family member or any individuals involved with the conduct of the study; and
  • Any condition that in the opinion of the investigator, might interfere with the vaccine evaluation.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00192127

Locations
United States, Florida
SFBC International, Inc
Miami, Florida, United States, 33181
Sponsors and Collaborators
MedImmune LLC
Investigators
Study Director: Robert Walker, MD Sponsor GmbH
  More Information

No publications provided

Responsible Party: Robert Walker, M.D., MedImmune Inc.
ClinicalTrials.gov Identifier: NCT00192127     History of Changes
Other Study ID Numbers: MI-CP113
Study First Received: September 12, 2005
Last Updated: December 12, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
 Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 16, 2013